Drug

Fibrinogen i 125

As of the edition of 20 October 2026, Fibrinogen i 125 is a drug: marketed, first approved in 1982 (US); acts on FGA, FGB and FGG; no US protection is listed.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Marketed; latest approval 1982
Kind
Unknown
Brand name
Ibrin
First approved
1 January 1982 (US)
Approvals on record
2 in 1 region
Holder of the most recent approval
Abbott; 2 holders in all

US protection

No US protection is listed.

The FDA registers list no drug-substance patent or exclusivity that counts for this drug.

This is the US only.

Targets

GeneProteinUniProt
FGAFibrinogen alpha chain [Cleaved into: Fibrinopeptide A; Fibrinogen alpha chain]P02671
FGBFibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]P02675
FGGFibrinogen gamma chainP02679

Who has held its approvals

CompanyRoleYears
AbbottApplicant
GE HealthcareLater holder